TWA
ABBV icon

Talisman Wealth Advisors’s AbbVie ABBV Stock Holding History

Talisman Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Buy
2,651
+346
+15% +$74.4K 0.5% 44
2026
Q1 		$501K Sell
2,305
-528
-19% -$117K 0.4% 56
2025
Q4 		$648K Sell
2,833
-27
-0.9% -$6.15K 0.5% 48
2025
Q3 		$662K Buy
2,860
+26
+0.9% +$5.29K 0.55% 45
2025
Q2 		$526K Sell
2,834
-48
-2% -$8.92K 0.48% 51
2025
Q1 		$604K Sell
2,882
-147
-5% -$28.6K 0.62% 46
2024
Q4 		$538K Sell
3,029
-54
-2% -$9.93K 0.57% 48
2024
Q3 		$602K Sell
3,083
-30
-1% -$5.6K 0.63% 43
2024
Q2 		$534K Buy
3,113
+99
+3% +$16.4K 0.62% 43
2024
Q1 		$549K Buy
3,014
+2
+0.1% +$345 0.69% 43
2023
Q4 		$467K Buy
3,012
+31
+1% +$4.52K 0.69% 42
2023
Q3 		$444K Buy
2,981
+70
+2% +$10.3K 0.77% 41
2023
Q2 		$392K Buy
2,911
+241
+9% +$35.3K 0.67% 47
2023
Q1 		$426K Buy
2,670
+425
+19% +$65K 0.77% 38
2022
Q4 		$363K Buy
+2,245
New +$344K 0.77% 41

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Talisman Wealth Advisors's ABBV Position: Q2 2026 in Review

Talisman Wealth Advisors increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $74.4K and bringing the position to 2,651 shares worth $667K. The position accounts for 0.5% of the portfolio, ranked #44.

Talisman Wealth Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Talisman Wealth Advisors held 2,651 shares of AbbVie worth $667K as of Q2 2026.
  • Talisman Wealth Advisors bought 346 AbbVie shares in Q2 2026, an estimated $74.4K.
  • AbbVie made up 0.5% of Talisman Wealth Advisors's portfolio in Q2 2026, its #44 holding.
  • Talisman Wealth Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Talisman Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.